Aptevo therapeutics inc. (APVO)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Operating Activities
Net income (loss)

-25,533

-40,448

-46,402

-52,040

-51,853

-53,689

0

0

0

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-109,471

-112,415

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

1,417

1,598

1,822

1,969

2,017

2,140

2,702

3,271

3,923

4,884

5,571

5,854

5,153

3,809

0

0

0

Depreciation and amortization

2,107

2,235

2,308

2,359

2,386

2,390

1,920

2,598

2,873

3,127

3,441

3,361

3,367

3,362

0

0

0

Gain on sale of Aptevo BioTherapeutics

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense and other

638

699

861

820

1,126

988

0

0

0

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-15,817

0

0

0

Change in fair value of contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

-444

0

0

0

Changes in operating assets and liabilities:
Accounts receivable

-

1,802

1,716

1,233

2,703

3,079

5,674

4,606

2,914

1,834

1,546

-2,998

703

-2,172

0

0

0

Inventories

-

4,354

3,513

3,997

3,061

757

2,732

1,042

-518

567

-4,159

-12,024

-14,090

-13,683

0

0

0

Prepaid expenses and other current assets

-2,164

-3,614

-4,943

-2,315

1,291

1,315

2,383

2,687

725

1,628

2,563

1,959

936

3,223

0

0

0

Operating lease right of use asset

977

945

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable, accrued compensation and other liabilities

-2,678

938

1,549

1,873

5,018

1,279

0

0

0

-

-

-

-

-

-

-

-

Long-term operating lease liability

896

1,039

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Sales rebates and discounts

-

-

-

-

-

-

-

-

-

-

-

-

-

-997

0

0

0

Accounts payable, accrued compensation and other liabilities

-

-

-

-

-

-

-

-

-

-

-

-2,462

-3,784

2,479

0

0

0

Changes in assets and liabilities held for sale

0

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Sales and rebates discounts

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-39,714

-42,383

-44,575

-48,173

-48,288

-51,422

0

0

0

-

-

-

-

-

-

-

-

Investing Activities
Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,454

0

0

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-34,777

-36,862

0

0

0

Proceeds from the maturity of investments

-

-

-

-

-

90,243

98,664

94,384

88,557

70,730

0

0

0

-

-

-

-

Cash received from sale of Aptevo BioTherapeutics

0

-

-

-

-

65

0

0

0

-

-

-

-

-

-

-

-

Purchases of property and equipment

-

153

202

562

656

976

1,224

999

1,081

1,402

1,684

1,503

2,235

2,512

0

0

0

Purchases of investments

-

-

-

-

-

16,535

86,876

105,888

91,493

99,633

0

0

0

-

-

-

-

Net cash (used in) provided by investing activities

32,370

4,097

13,138

36,837

49,132

72,797

0

0

0

-

-

-

-

-

-

-

-

Financing Activities
Payments of long-term debt, including exit and other fees

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of tax liability for vested equity awards

-

-

-

-

-

808

0

0

0

-

-

-

-

-

-

-

-

Proceeds of issuance of common stock, warrants, and pre-funded warrants, net

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Payment of tax liability for vested equity awards

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Proceeds from exercise of common stock options

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Proceeds from issuance of prefunded warrants

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Value of equity awards withheld for tax liability

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-49,153

-47,394

0

0

0

Transfer from former parent, prior to spin-off

-

-

-

-

-

-

-

-

-

-

-

-

-

71,219

0

0

0

Settlement of contribution receivable from former parent

-

-

-

-

-

-

-

-

-

20,000

0

0

0

-

-

-

-

Net cash provided by (used in) financing activities

-22,328

20,149

20,323

19,716

20,142

-787

0

0

0

-

-

-

-

-

-

-

-

Contingent consideration payments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash (used in) provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

94,871

89,295

0

0

0

Increase (decrease) in cash, cash equivalents, and restricted cash

-29,672

-18,137

-11,114

8,380

20,986

20,588

-49,935

-2,594

9,059

7,419

0

0

0

-

-

-

-

(Decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

5,039

0

0

0